Cord blood transplantation in patients with hemoglobinopathies

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells.

Original languageEnglish
Pages (from-to)277-281
Number of pages5
JournalTransfusion and Apheresis Science
Volume42
Issue number3
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Hemoglobinopathies
Fetal Blood
Transplantation
Thalassemia
Homologous Transplantation
Sickle Cell Anemia
Graft vs Host Disease
Bone Marrow Cells
Developing Countries
Tissue Donors
Morbidity
Mortality
Incidence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Cord blood transplantation in patients with hemoglobinopathies. / Boncimino, Agata; Bertaina, Alice; Locatelli, Franco.

In: Transfusion and Apheresis Science, Vol. 42, No. 3, 06.2010, p. 277-281.

Research output: Contribution to journalArticle

@article{4f711312005e468db839dcd05e22ce63,
title = "Cord blood transplantation in patients with hemoglobinopathies",
abstract = "Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells.",
author = "Agata Boncimino and Alice Bertaina and Franco Locatelli",
year = "2010",
month = "6",
doi = "10.1016/j.transci.2010.03.006",
language = "English",
volume = "42",
pages = "277--281",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Cord blood transplantation in patients with hemoglobinopathies

AU - Boncimino, Agata

AU - Bertaina, Alice

AU - Locatelli, Franco

PY - 2010/6

Y1 - 2010/6

N2 - Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells.

AB - Despite the optimization of conventional treatment, both thalassemia and sickle cell disease are still associated with significant morbidity and mortality, especially in developing countries. Allogeneic transplantation of hematopoietic progenitors is the only curative treatment and represents an attractive option for these patients. In view of the low incidence of graft-versus-host disease associated with the procedure, allogeneic cord blood transplantation (CBT) is particularly appealing for patients with non-malignant disorders. Available evidence indicates that related donor CBT is a safe and effective option for patients with hemoglobinopathies, able to offer results at least as good as those reported using bone marrow cells.

UR - http://www.scopus.com/inward/record.url?scp=77953022728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953022728&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2010.03.006

DO - 10.1016/j.transci.2010.03.006

M3 - Article

C2 - 20382570

AN - SCOPUS:77953022728

VL - 42

SP - 277

EP - 281

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -